Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 245 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Calcium pre-treatment Clear all
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 6, 2026, 2:41 AM EDT
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 6, 2026, 2:41 AM EDT
Active, not recruiting Phase 2 Interventional

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

NCT00871013
View directory record Official record
Conditions
Myeloma
Interventions
Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 6, 2026, 2:41 AM EDT
Recruiting Phase 2Phase 3 Interventional

Surviving PEA in Roanoke (SPEAR) Study

NCT05283850
View directory record Official record
Conditions
Cardiac Arrest, Pulseless Electrical Activity
Interventions
High Calcium, Low Sodium (HCLS) Crystalloid Therapy, High Calcium, High Sodium (HCHS) Crystalloid Therapy
Drug
Lead sponsor
Carol Bernier
Other
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 6, 2026, 2:41 AM EDT
Terminated Not applicable Interventional Results available

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

NCT02491411
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
Interventions
Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 6, 2026, 2:41 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

NCT07601100
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib, Dexamethesone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 6, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional Results available

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

NCT00998738
View directory record Official record
Conditions
Neuropathy, Pain, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Calcium Gluconate, Magnesium Sulfate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Ixabepilone
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

NCT04191616
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Pomalidomide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CARDIA-Salt Sensitivity of Blood Pressure (SSBP)

NCT04258332
View directory record Official record
Conditions
Salt Sensitivity of Blood Pressure, Hypertension
Interventions
High Salt Diet, Low Salt Diet
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 70 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 6, 2026, 2:41 AM EDT
Recruiting Phase 2 Interventional

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

NCT06821997
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Sucrosofate, Leucovorin Calcium, Oxaliplatin, Surgical Procedure
Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT

NCT01672801
View directory record Official record
Conditions
Unexplained Infertility, Polycystic Ovarian Syndrome, Anovulatory
Interventions
Placebo, Nimodipine
Drug
Lead sponsor
Boston IVF
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 6, 2026, 2:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 6, 2026, 2:41 AM EDT
Active, not recruiting Phase 2 Interventional

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

NCT05753215
View directory record Official record
Conditions
Bone Infection, Joint Infection, Bone and Joint Infection
Interventions
Omadacycline Pill, Standard of Care
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

NCT03202628
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest

NCT01509040
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Standard Care, Low Volume Hemofiltration, High Volume Hemofiltration
Other · Device
Lead sponsor
University of Washington
Other
Eligibility
65 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 6, 2026, 2:41 AM EDT
Not listed Phase 2 Interventional

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

NCT04668976
View directory record Official record
Conditions
Colorectal Cancer, Cholangiocarcinoma
Interventions
Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab)
Device · Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Inovium Ovarian Rejuvenation Trials

NCT03178695
View directory record Official record
Conditions
Perimenopausal Disorder, Menopause, Menopause, Premature, Menopause Related Conditions, Menopause Premature Symptomatic, Menopause Premature Asymptomatic, Premature Ovarian Failure, Premature Ovarian Failure, Familial, Premature Ovarian Failure 2A, Premature Ovarian Failure 3, Premature Ovarian Failure 4, Premature Ovarian Failure 1, Premature Ovarian Failure 5, Premature Ovarian Failure 6, Premature Ovarian Failure 7, Premature Ovarian Failure 9, Premature Ovarian Failure 8, Infertility, Infertility, Female, Infertility Unexplained
Interventions
Autologous PRP injection into human ovarian tissue
Other
Lead sponsor
Ascendance Biomedical
Industry
Eligibility
35 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 6, 2026, 2:41 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 6, 2026, 2:41 AM EDT
Recruiting Phase 2 Interventional

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU), FLOT Chemotherapy, Calcium folinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

NCT00402766
View directory record Official record
Conditions
Mesothelioma
Interventions
Cisplatin, Imatinib Mesylate, Pemetrexed, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 6, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

NCT01814501
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
panitumumab, irinotecan hydrochloride, fluorouracil, leucovorin calcium
Biological · Drug
Lead sponsor
John Hays
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 6, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional Results available

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

NCT03050814
View directory record Official record
Conditions
Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions
Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 6, 2026, 2:41 AM EDT
Recruiting Phase 1 Interventional

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT05476770
View directory record Official record
Conditions
Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions
Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 6, 2026, 2:41 AM EDT